LEADER 05438nam 22007095 450 001 9910437824103321 005 20200705073339.0 010 $a1-4614-5480-8 024 7 $a10.1007/978-1-4614-5480-9 035 $a(CKB)2670000000277893 035 $a(EBL)1081931 035 $a(OCoLC)819379531 035 $a(SSID)ssj0000798786 035 $a(PQKBManifestationID)11429289 035 $a(PQKBTitleCode)TC0000798786 035 $a(PQKBWorkID)10754630 035 $a(PQKB)10941887 035 $a(DE-He213)978-1-4614-5480-9 035 $a(MiAaPQ)EBC1081931 035 $a(PPN)168303140 035 $a(EXLCZ)992670000000277893 100 $a20121026d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Immunological Barriers to Regenerative Medicine$b[electronic resource] /$fedited by Paul J. Fairchild 205 $a1st ed. 2013. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Humana,$d2013. 215 $a1 online resource (333 p.) 225 1 $aStem Cell Biology and Regenerative Medicine,$x2196-8985 300 $aDescription based upon print version of record. 311 $a1-4899-9932-9 311 $a1-4614-5479-4 320 $aIncludes bibliographical references and index. 327 $aMechanisms of Immune Rejection of Stem Cell-Derived Tissues: Insights from Organ Transplantation -- The Immunogenicity of ES Cells and their Progeny -- Interaction of Embryonic Stem Cells with the Immune System -- The Role of NK cells and T Cells in the Rejection of Embryonic Stem Cell-Derived Tissues -- Mitigating the Risks of Immunogenicity in the Pursuit of Induced Pluripotency -- Thymic Involution: A Barrier or Opportunity for Cell Replacement Therapy? -- Construction of Stem Cell Banks: Prospects for Tissue Matching -- Generation of Histocompatible Tissues via Parthenogenesis -- Prospects for Designing ?Universal? Stem Cell Lines -- The Immunosuppressive Properties of Adult Stem Cells: MSC as a Case Study -- The Immunogenicity of Stem Cells and Thymus-Based Strategies to Minimise Immune Rejection -- The Induction of Mixed Chimerism Using ES Cell-Derived Hematopoietic Stem Cells -- Prospects for the Induction of Transplant Tolerance Using Dendritic Cells -- Strategies for the Induction of Tolerance with Monoclonal Antibodies -- Induction of Immunological Tolerance to Transgene Products -- Addressing the Challenge of Autoimmunity in the Treatment of Diabetes with Stem Cells. 330 $aRecent years have witnessed numerous advances in stem cell research that have suggested novel strategies for the treatment of the chronic and regenerative diseases that pose a growing challenge to the provision of healthcare in the 21st century.  Nevertheless, there is little doubt that related disciplines have failed to keep pace with such developments, of which the immunology of transplant rejection is perhaps the most relevant to the nascent field of regenerative medicine.  Indeed, given that after decades of research into the mechanisms of organ allograft rejection, we remain wholly dependent on immune suppression to ensure acceptance of foreign tissues, we might legitimately ask whether there is any reason why tissues differentiated from stem cells might not suffer the same fate.  This volume seeks to address this issue by drawing on the principles of alloantigen recognition to assess the validity of early convictions that embryonic stem cell-derived tissues may prove invisible to the immune system of the host and the more recent belief that induced pluripotent stem cells, derived in a fully autologous manner, will circumvent the issue of immunogenicity.  Having debunked such assumptions and established the magnitude of the immunological barriers to be overcome, this book then draws on the expertise of internationally-recognised laboratories around the world to provide a critical assessment of the likely success of applying strategies such as stem cell banking, silencing of genes that confer immunogenicity, and the induction of transplantation tolerance to overcoming the immunological barriers in the future.  Indeed, it is only through reaching a consensus in the field that enduring solutions to such an intractable problem may ultimately emerge. 410 0$aStem Cell Biology and Regenerative Medicine,$x2196-8985 606 $aStem cells 606 $aImmunology 606 $aCell biology 606 $aBiotechnology 606 $aStem Cells$3https://scigraph.springernature.com/ontologies/product-market-codes/L16010 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 606 $aCell Biology$3https://scigraph.springernature.com/ontologies/product-market-codes/L16008 606 $aBiotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/C12002 615 0$aStem cells. 615 0$aImmunology. 615 0$aCell biology. 615 0$aBiotechnology. 615 14$aStem Cells. 615 24$aImmunology. 615 24$aCell Biology. 615 24$aBiotechnology. 676 $a616.02/774 676 $a616.02774 702 $aFairchild$b Paul J$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910437824103321 996 $aThe Immunological Barriers to Regenerative Medicine$92542149 997 $aUNINA